EBOS Reports Another Record Result and Continued Double-Digit Growth
Key highlights of the first half included:
- Revenue of $5.3 billion (up 12.8%);
- Underlying Net Profit after Tax of $109.3 million (up 15.8%);
- $7.4 million of M&A transaction costs (post-tax) were incurred in Statutory NPAT.
- Underlying EPS of 66.6 cents up 15.2%;
- Interim dividend declared of NZ 47.0 cents per share (up 10.6%);
- Continued strong performances from both our Healthcare and Animal Care segments, with Healthcare’s Underlying EBIT up 17.0% and Animal Care’s EBIT up 14.9%;
- Operating cash flow of $106.8 million (up 8.1%);
- Consistent with our strategy of investing for growth and as previously announced:
- the Group completed three acquisitions to further expand its Institutional Healthcare division, including Sentry Medical, Pioneer Medical and MD Solutions; and
- the Group reached agreement to acquire LifeHealthcare, which will establish EBOS as a leading distributor of medical devices in Australia, New Zealand and South East Asia.
- Commenced the commissioning phase of our new state of the art pet food manufacturing facility in Parkes, NSW.
EBOS Group Limited (“EBOS” or the “Group”) today announced another record result for the first half of the 2022 financial year, including double-digit underlying earnings growth.
In commenting on today’s results announcement, EBOS Chief Executive Officer, John Cullity said:
“We are pleased to report another record result for EBOS on the back of particularly strong revenue growth across our key Healthcare and Animal Care segments.”
“Both segments continued their strong growth trajectory, reinforcing the value of our diverse portfolio of businesses and the successful execution of our strategy of pursuing both organic and inorganic growth.”
“The strong growth of our Healthcare segment was driven by our Community Pharmacy, TerryWhite Chemmart (“TWC”), Institutional Healthcare and Contract Logistics businesses. The Community Pharmacy division’s performance was particularly pleasing, resulting from customer growth, market share gains and the return of Pfizer’s retail pharmacy volumes to the wholesale channel.”
